Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › cardiotoxicity

Cardiotoxicity

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for cardiotoxicity

2 trials tracked for cardiotoxicity.

2Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 1 2
  1. Phase 1 Staccato Prochlorperazine Thorough QT/QTc Completed
  2. Phase 1 Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
ACEIs and Beta Blockers Show Cardioprotective Effects in Chemotherapy
Oncology Meta-analysis
ACEIs and Beta Blockers Show Cardioprotective Effects in Chemotherapy ACE Inhibitors and Beta Blockers May Protect Hearts During Chemotherapy
An umbrella review of 35 meta-analyses finds ACEIs and beta blockers modestly preserve cardiac function and reduce heart failure risk during…
Specific heart medications like ACE inhibitors and beta blockers may help protect heart function in patients undergoing chemotherapy treatme…
Jun 20, 2026
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients
Oncology Cohort
Retrospective analysis identifies risk factors for trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients Many Breast Cancer Patients Can Avoid Heart Damage — If Doctors Know the Warning Signs
This retrospective analysis of 298 HER2-positive breast cancer patients assessed trastuzumab-induced cardiotoxicity.
This could help doctors protect patients’ hearts before cancer therapy even begins.
Frontiers Apr 23, 2026
Meta-analysis finds beta-blockers may reduce cardiotoxicity risk during cancer therapy
Cardiology Meta-analysis
Meta-analysis finds beta-blockers may reduce cardiotoxicity risk during cancer therapy Heart-Protecting Meds Show Promise for Cancer Patients
A meta-analysis of 19 RCTs in patients receiving anthracyclines and/or trastuzumab found beta-blockers improved LVEF (WMD=2.19) and reduced…
Two specific heart medications stand out as the most effective shields against heart damage caused by powerful cancer treatments.
Frontiers Apr 13, 2026